STOCK TITAN

[S-8 POS] Unity Biotechnology, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
S-8 POS
Rhea-AI Filing Summary

Unity Biotechnology filed Post-Effective Amendment No. 1 to terminate effectiveness of multiple Form S-8 registration statements and remove from registration any and all shares of its common stock that remained unsold under those S-8 filings. The amendment lists ten S-8 registration numbers and the original registered share amounts for various equity plans, and states the Registration Statements are amended to reflect the deregistration.

Unity Biotechnology ha depositato l'Emendamento post-effettivo n. 1 per porre fine all'efficacia di più dichiarazioni di registrazione Modulo S-8 e rimuovere dalla registrazione tutte le azioni ordinarie rimaste invendute relative a tali S-8. L'emendamento elenca dieci numeri di registrazione S-8 e gli importi originariamente registrati per vari piani azionari, dichiarando che le Dichiarazioni di Registrazione sono modificate per riflettere la deregistrazione.

Unity Biotechnology presentó la Enmienda postefectiva n.º 1 para terminar la vigencia de múltiples declaraciones de registro Formulario S-8 y eliminar de la inscripción todas las acciones ordinarias que permanecían sin vender bajo esas presentaciones S-8. La enmienda enumera diez números de registro S-8 y los importes originalmente registrados para varios planes de acciones, y expresa que las Declaraciones de Registro se modifican para reflejar la desregistro.

Unity Biotechnology는 여러 Form S-8 등록서의 효력을 종료하고 해당 S-8 등록에 따라 아직 판매되지 않은 보통주 전부를 등록에서 제외하기 위해 사후 발효 수정안(Post-Effective Amendment) No. 1을 제출했습니다. 이 수정안에는 10개의 S-8 등록번호와 다양한 주식 플랜에 대해 원래 등록된 주식 수가 기재되어 있으며, 등록서류가 등록 말소를 반영하도록 수정되었음을 명시하고 있습니다.

Unity Biotechnology a déposé l'Amendement post-effectif n°1 afin de mettre fin à l'efficacité de plusieurs déclarations d'enregistrement Form S-8 et de retirer de l'enregistrement toutes les actions ordinaires encore invendues au titre de ces dépôts S-8. L'amendement énumère dix numéros d'enregistrement S-8 et les quantités initialement enregistrées pour divers plans d'actions, et indique que les déclarations d'enregistrement sont modifiées pour refléter la radiation.

Unity Biotechnology hat die Post-Effective Amendment Nr. 1 eingereicht, um die Wirksamkeit mehrerer Form S-8-Registrierungserklärungen zu beenden und alle unter diesen S-8-Anmeldungen noch unveräußerten Stammaktien aus der Registrierung zu entfernen. Die Änderung listet zehn S-8-Registrierungsnummern sowie die ursprünglich registrierten Stückzahlen für verschiedene Aktienpläne auf und erklärt, dass die Registrierungserklärungen zur Darstellung der Delistung geändert werden.

Positive
  • Administrative clarity: The filing explicitly deregisters unsold shares from ten S-8 registration statements.
  • Comprehensive list: Each affected registration number and the originally registered share amounts are listed for transparency.
Negative
  • None.

Insights

TL;DR: Routine post-effective amendment deregisters unsold S-8 shares across several registration statements.

The filing formally terminates the effectiveness of ten Form S-8 registrations and removes the unsold shares described in each registration from registration. This is an administrative action reflecting that the Company no longer needs those registered shares available under the listed plans. The document lists each S-8 number and the originally registered share amounts for the Company's equity plans.

TL;DR: Administrative update with no disclosed financial impact.

The amendment documents deregistration of remaining unsold securities under specified S-8 filings and updates the registration records accordingly. The filing does not present financial results, transfers, or changes to plan terms; it simply removes unsold shares from registration as permitted by the undertakings in the registration statements.

Unity Biotechnology ha depositato l'Emendamento post-effettivo n. 1 per porre fine all'efficacia di più dichiarazioni di registrazione Modulo S-8 e rimuovere dalla registrazione tutte le azioni ordinarie rimaste invendute relative a tali S-8. L'emendamento elenca dieci numeri di registrazione S-8 e gli importi originariamente registrati per vari piani azionari, dichiarando che le Dichiarazioni di Registrazione sono modificate per riflettere la deregistrazione.

Unity Biotechnology presentó la Enmienda postefectiva n.º 1 para terminar la vigencia de múltiples declaraciones de registro Formulario S-8 y eliminar de la inscripción todas las acciones ordinarias que permanecían sin vender bajo esas presentaciones S-8. La enmienda enumera diez números de registro S-8 y los importes originalmente registrados para varios planes de acciones, y expresa que las Declaraciones de Registro se modifican para reflejar la desregistro.

Unity Biotechnology는 여러 Form S-8 등록서의 효력을 종료하고 해당 S-8 등록에 따라 아직 판매되지 않은 보통주 전부를 등록에서 제외하기 위해 사후 발효 수정안(Post-Effective Amendment) No. 1을 제출했습니다. 이 수정안에는 10개의 S-8 등록번호와 다양한 주식 플랜에 대해 원래 등록된 주식 수가 기재되어 있으며, 등록서류가 등록 말소를 반영하도록 수정되었음을 명시하고 있습니다.

Unity Biotechnology a déposé l'Amendement post-effectif n°1 afin de mettre fin à l'efficacité de plusieurs déclarations d'enregistrement Form S-8 et de retirer de l'enregistrement toutes les actions ordinaires encore invendues au titre de ces dépôts S-8. L'amendement énumère dix numéros d'enregistrement S-8 et les quantités initialement enregistrées pour divers plans d'actions, et indique que les déclarations d'enregistrement sont modifiées pour refléter la radiation.

Unity Biotechnology hat die Post-Effective Amendment Nr. 1 eingereicht, um die Wirksamkeit mehrerer Form S-8-Registrierungserklärungen zu beenden und alle unter diesen S-8-Anmeldungen noch unveräußerten Stammaktien aus der Registrierung zu entfernen. Die Änderung listet zehn S-8-Registrierungsnummern sowie die ursprünglich registrierten Stückzahlen für verschiedene Aktienpläne auf und erklärt, dass die Registrierungserklärungen zur Darstellung der Delistung geändert werden.

As filed with the Securities and Exchange Commission on August 25, 2025

Registration No. 333-224726

Registration No. 333-230086

Registration No. 333-237088

Registration No. 333-237474

Registration No. 333-250926

Registration No. 333-254619

Registration No. 333-263576

Registration No. 333-270567

Registration No. 333-278679

Registration No. 333-285649

 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-224726

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-230086

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-237088

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-237474

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-250926

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-254619

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-263576

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-270567

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-278679

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-285649

 

 

FORM S-8

REGISTRATION STATEMENT

Under

The Securities Act of 1933

 

 

UNITY BIOTECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   26-4726035
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification Number)

124 Washington Street, Suite 101

Foxborough, Massachusetts 02035

(508) 543-1720

(Address of Principal Executive Offices)

Unity Biotechnology, Inc. 2013 Equity Incentive Plan

Unity Biotechnology, Inc. 2018 Incentive Award Plan

Unity Biotechnology, Inc. 2018 Employee Stock Purchase Plan

Unity Biotechnology, Inc. 2020 Employment Inducement Incentive Award Plan

(Full Title of the Plans)

Craig R. Jalbert

President, Secretary, and Director

Unity Biotechnology, Inc.

124 Washington Street, Suite 101

Foxborough, Massachusetts 02035

(508) 543-1720

(Name and address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copies to:

Erica Kassman

Latham & Watkins LLP

140 Scott Drive

Menlo Park, CA 94025

Telephone: (650) 328-4600

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 
 


EXPLANATORY NOTE

DEREGISTRATION OF SECURITIES

This Post-Effective Amendment No. 1 (“Post-Effective Amendment No. 1”) filed by Unity Biotechnology, Inc., a Delaware corporation (the “Company”), removes from registration all shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), registered under the following Registration Statements on Form S-8 (each a “Registration Statement” and, collectively, the “Registration Statements”) filed with the U.S. Securities and Exchange Commission (the “Commission”) that remain unsold thereunder:

 

   

Registration Statement on Form S-8 (No. 333-224726), filed with the Commission on May 7, 2018, pertaining to the registration of (i) 5,293,729 shares of the Company’s Common Stock under the Company’s 2013 Equity Incentive Plan and 2018 Incentive Award Plan, (ii) 3,330,530 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, and (iii) 536,242 shares of the Company’s Common Stock under the Company’s 2018 Employee Stock Purchase Plan.

 

   

Registration Statement on Form S-8 (No. 333-230086), filed with the Commission on March 6, 2019, pertaining to the registration of (i) 2,125,510 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, and (ii) 424,143 shares of the Company’s Common Stock under the Company’s 2018 Employee Stock Purchase Plan.

 

   

Registration Statement on Form S-8 (No. 333-237088), filed with the Commission on March 11, 2020, pertaining to the registration of (i) 2,361,841 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, and (ii) 472,271 shares of the Company’s Common Stock under the Company’s 2018 Employee Stock Purchase Plan.

 

   

Registration Statement on Form S-8 (No. 333-237474), filed with the Commission on March 30, 2020, pertaining to the registration of 1,100,000 shares of the Company’s Common Stock under the Company’s 2020 Employment Inducement Incentive Award Plan.

 

   

Registration Statement on Form S-8 (No. 333-250926), filed with the Commission on November 24, 2020, pertaining to the registration of 1,500,000 shares of the Company’s Common Stock under the Company’s 2020 Employment Inducement Incentive Award Plan, as amended.

 

   

Registration Statement on Form S-8 (No. 333-254619), filed with the Commission on March 23, 2021, pertaining to the registration of (i) 2,675,309 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, and (ii) 532,480 shares of the Company’s Common Stock under the Company’s 2018 Employee Stock Purchase Plan.

 

   

Registration Statement on Form S-8 (No. 333-263576), filed with the Commission on March 15, 2022, pertaining to the registration of (i) 3,182,965 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, and (ii) 629,919 shares of the Company’s Common Stock under the Company’s 2018 Employee Stock Purchase Plan.

 

   

Registration Statement on Form S-8 (No. 333-270567), filed with the Commission on March 15, 2023, pertaining to the registration of (i) 710,765 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, (ii) 142,153 shares of the Company’s Common Stock under the Company’s 2018 Employee Stock Purchase Plan, and (iii) 300,000 shares of the Company’s Common Stock under the Company’s 2020 Employment Inducement Incentive Award Plan, as amended.

 

   

Registration Statement on Form S-8 (No. 333-278679), filed with the Commission on April 15, 2024, pertaining to the registration of (i) 839,248 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, and (ii) 167,849 shares of the Company’s Common Stock under the 2018 Employee Stock Purchase Plan.


   

Registration Statement on Form S-8 (No. 333-285649), filed with the Commission on March 7, 2025, pertaining to the registration of (i) 843,260 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, and (ii) 168,652 shares of the Company’s Common Stock under the Company’s 2018 Employee Stock Purchase Plan.

As previously reported on June 27, 2025, the board of directors of the Company: (i) determined that it is in the best interests of the Company and its stakeholders that the Company be liquidated and dissolved in accordance with the Delaware General Corporation Law pursuant to a Plan of Complete Liquidation and Dissolution (the “Dissolution”); and (ii) approved seeking stockholder approval to proceed with the Dissolution pursuant to Delaware law at a special meeting of stockholders and, if approved by stockholders, file a Certificate of Dissolution with the Secretary of State of the State of Delaware. In connection with the foregoing, the Company has determined to terminate the offerings of securities under the Registration Statements. Accordingly, the Company is filing this Post-Effective Amendment No. 1 to terminate the effectiveness of the Registration Statements, and, in accordance with the undertakings made by the Company in the Registration Statements, to remove from registration any and all of the securities that remain unsold under the Registration Statements as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of all such securities. Note that the numbers of securities listed above do not take into account any applicable corporate actions, such as stock splits, that may have been taken in the interim.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Foxborough in the Commonwealth of Massachusetts, on August 25, 2025.

 

UNITY BIOTECHNOLOGY, INC.
By:   /s/ Craig R. Jalbert
  Title: President, Secretary, and Director

No other person is required to sign this Post-Effective Amendment No. 1 to the Registration Statements on Form S-8 in reliance on Rule 478 of the Securities Act of 1933, as amended.

FAQ

What did Unity Biotechnology (UBX) file in this Post-Effective Amendment No. 1?

Answer: The Company filed a Post-Effective Amendment to terminate effectiveness of multiple Form S-8 registration statements and remove from registration any unsold shares under those statements.

Which registration statements does the amendment terminate?

Answer: The amendment lists S-8 registration numbers 333-224726, 333-230086, 333-237088, 333-237474, 333-250926, 333-254619, 333-263576, 333-270567, 333-278679, and 333-285649.

Does the filing state the number of shares removed from registration?

Answer: The filing lists the originally registered share amounts for each S-8 (for example, 5,293,729 shares under 333-224726 and 843,260 shares under 333-285649) and states it removes any unsold shares remaining as of the date hereof.

Does the amendment indicate any change to equity plan terms or sales of shares?

Answer: No. The amendment only deregisters unsold securities; it does not disclose changes to plan terms or any share issuances.

Who signed the filing for Unity Biotechnology?

Answer: The filing is signed by Craig R. Jalbert, identified as President, Secretary, and Director.
Unity Btech

NASDAQ:UBX

UBX Rankings

UBX Latest News

UBX Latest SEC Filings

UBX Stock Data

5.13M
16.88M
1.9%
17.19%
3.33%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO